As the only central enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council specializing in life and health, China National Pharmaceutical Group Corporation (hereinafter referred to as “Sinopharm”) is a national innovative enterprise, a central pharmaceutical reserve unit, and a leading comprehensive pharmaceutical and health industry group in China and Asia in terms of comprehensive strength and scale, with a comprehensive health industry chain integrating technical R & D, industrial manufacturing, logistics and distribution, retail chain, medical and health care, engineering technology, professional exhibition, international operation and financial investment etc.

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 4 products have been launched in China, 1 in the European Union (EU), 3 New Drug Applications (NDAs) accepted for review in China.

Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading innovation-driven international healthcare group in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma’s business extends to pharmaceutical distribution and retail.

Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.

Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.

Founded in 1999, Jemincare is a leading health industry group in China. Headquartered in Nanchang, China, Jemincare has more than 12,000 employees and its business covers the fields of medicine and health, clean energy, green mineral development and industrial investment. In 2021, its revenue will exceed 41 billion yuan. Adhering to the innovation-driven strategy, Jemincare provides reliable guarantee for human health through endogenous growth, extension expansion and integrated development, and promotes global green and sustainable development. Jemincare is committed to becoming an international advanced modern big health industry group.

Jemincare has established an integrated international pharmaceutical RESEARCH and development system in Shanghai, Nanjing and New Jersey, USA. By setting up 10 pharmaceutical bases in Jiangxi, Jiangsu, Zhejiang, Jilin and other provinces, Jemincare promotes the global development and transformation of cutting-edge technologies and products such as biological macromolecules, chemical small molecules and innovative Traditional Chinese medicine. Our products have been exported to more than 30 countries and regions in Europe and America, ranking among the top ten of the Top 100 pharmaceutical industry in China for many consecutive years.

Qyuns Therapeutics was established in 2015, and the founding team consists of overseas returnee doctors and senior experts in the domestic biopharmaceutical industry.

The company specializes in the R&D of antibody drugs in the field of autoimmunity and allergy, and is committed to developing, manufacturing and selling therapeutic antibody drugs that meet international specifications and specifications.

Through completely independent R&D, the company has formed a product line of 12 innovative varieties, covering the autoimmunity and allergy-related fields of psoriasis, atopic dermatitis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, asthm, etc.

Ascletis Pharma Inc. was established in 2013, and was listed on the Hong Kong Stock Exchange in 2018 (1672.HK).

Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, non-alcoholic steatohepatitis/primary biliary cholangitis, and tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors) to address clinical needs of patients at home and abroad.

Gannex, a wholly-owned subsidiary of Ascletis, is fully dedicated to R&D and commercialization of new drugs in the field of NASH.

MAB Works is a clinical-stage biopharmaceutical company in China, focusing on discovery and development of innovative and differentiated antibody drugs. We strive to become a globally integrated biopharmaceutical company.

Our mission is to transform the scientific breakthrough of immunology and carcinobiology into novel antibody therapies, covering the biologic drug market of oncology and autoimmune diseases, which is a market growing rapidly globally and in China, with unmet clinical demand.

We will leverage this opportunity to bring innovative and affordable treatment regimens for patients in such fields continuously.

Founded in 2010, Binhui Biopharmaceutical Co., Ltd. is a leading independent company of oncolytic virus immunotherapy in China, devoting to research and development in OV for more than ten years.

The company created the oncolytic virus (OV) technology platform, its first product has obtained 3 IND approvals for OV mono and combo therapies, and is the only product conducted multiple Phase II clinical trials for mono and combo therapies with OV in various indications in China, which showed promising therapeutic effect.

In August 2021, BS001(OH2) injection was approved by the U.S. FDA for clinical trial of various indications in the US.

Jiangsu Recbio Co., Ltd. (Recbio or The Company) is an innovative vaccine company dedicated to the development and commercialization of safer and more effective innovative vaccines to address the public health need that is far from being met.

Recbio has high-value vaccine portfolio driven by self-developed novel adjuvant technologies and protein engineering technologies.

Through its strong R&D capabilities, the company has built a robust and innovative vaccine portfolio of 11 vaccine candidates, with coverage strategically expanding to areas covered by 5 of the top 10 most expensive diseases in the Global Burden of Disease assessed by the World Health Organization's DALYs released in 2019, and 3 of the top 5 best-selling vaccine products in the world in 2020.

CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs.

The group’s total assets are 50 billion RMB, with 27000 employees.

Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI.

In 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group.

At present, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin, and other provinces and cities. The products are sold in more than 100 countries and regions around the world, and 36 single varieties sold over 100 million RMB.

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd.

Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics, including the R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc., and the pilot platform for stock solutions and preparations in compliance with applicable GMP standards.

Disposable technology and the world's leading 200L and 1000L disposable bioreactors from GE were employed in the DS pilot production. The preparations workshop is equipped with complete sets of vials and prefilled syringe filling lines imported from BOSCH Germany, supporting various ways of administration. The quality control lab has a variety of advanced analytical instruments fulfilling the analytical needs, such as product release and stability studies, of supporting production, registration, and clinical trials.

Guangzhou Pharmaceutical Holdings Limited (GPHL) is a wholly state-owned enterprise authorized by Guangzhou municipal government to operate state-owned assets. GPHL is dedicated to the research and development of Chinese patent medicine, Chinese herbal medicine, chemical pharmaceutical raw materials and preparations, biological medicine and healthcare products, and to pharmaceutical logistics and distribution and healthcare service. As a large enterprise winning the municipal government's key support for development, GPHL integrates the research, manufacturing and trading of medicine.

Founded in 2002, Guojian Pharmaceutical is one of the first batch of Chinese innovative biopharmaceutical enterprises focusing on antibody drugs and is also a domestic pharmaceutical enterprise with three listed therapeutic antibody drugs in China. It has grown to become a biopharmaceutical company in China with independent capabilities in research and development, manufacturing and commercialization.

With the National Engineering Research Center of Antibody Medicine, the company operates the production base of antibody drugs with a total scale of more than 40,000 liters.

The company's R&D mainly focuses on innovative therapeutic antibody drugs, and provides high-quality, safe and effective clinical solutions for the treatment of autoimmune diseases, tumors and other major diseases.

Adhering to the concept of "Cherish Life, Care for Life, Create Life", Guojian Pharmaceutical is committed to growing an innovative therapeutic antibody drug enterprise that benefits China and embraces the world, realizing the vision of "making innovative antibody drugs within reach", so as to benefit more people and contribute to the Healthy China.

As an innovation-driven biotechnology company, Genrixbio (Shanghai) Technology Co., Ltd. (hereinafter referred to as Genrixbio) was jointly founded by a number of senior experts in the biopharmaceutical industry and the actual controller of the A-share listed company Genrixbio in Zhangjiang, Shanghai in June 2014. The company is engaged in the development and industrialization of biotechnology drugs such as therapeutic monoclonal antibodies and fusion proteins. We have established several technical platforms covering the whole life cycle of antibody drug development, including discovery and screening of innovative antibody drugs, process development and quality characterization of highly expressed cell lines of antibody drugs, pilot and industrialized process scale-up production, pharmacological and toxicological research, clinical research and registration filing, etc.

Currently, a number of innovative drugs developed by the company have entered the clinical study stage, with indications including multiple oncology and autoimmune system diseases, and more than a dozen high-potential innovative varieties are in various stages of druggability assessment , pre-clinical study or preparation for IND application.

Founded in 2017, Immune-path Biotechnology (Suzhou) Co., Ltd. is led by national specially-appointed experts, and founded by vaccine R&D professionals at home and abroad and an elite team of pharmaceutical companies.

The company is a high-tech biopharmaceutical enterprise headquartered in Suzhou High-tech Zone. It is invested by a number of top domestic and foreign funds, including Lilly Asia Ventures, Qiming Venture Capital, Orbimed, Loyal Valley Capital, Northern Light Venture Capital, Bio Venture, Green Pine Capital, and SND Group.

Huadong Medicine Co., Ltd.  (stock code: 000963) was founded in 1993, headquartered in Hangzhou, Zhejiang Province, and listed on the Shenzhen Stock Exchange in December 1999.

Dominated by the pharmaceutical industry, while expanding the pharmaceutical business and medical beauty industry, the company's business covers the entire pharmaceutical industry chain, and has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical research and development, production and distribution.

The company has always adhered to the corporate philosophy of “scientific research-based and patient-centered” and is committed to becoming a top international pharmaceutical enterprise driven by scientific research and innovation.

With more than 10,000 employees, the company's operating revenue in 2020 was RMB 33.683 billion, net profit attributable to owners of the parent company was RMB 2.820 billion, and the company's return on equity (ROE) has exceeded 20% for 14 consecutive years.